| 53.48 3.31 (6.6%) | 04-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 66.01  |
1-year : | 75.97 |
| Resists | First : | 56.51 |
Second : | 65.05 |
| Pivot price | 49.97 |
|||
| Supports | First : | 42.72 | Second : | 35.54 |
| MAs | MA(5) : | 48.34 |
MA(20) : | 51.74 |
| MA(100) : | 61.01 |
MA(250) : | 37.92 |
|
| MACD | MACD : | -4.4 |
Signal : | -5.3 |
| %K %D | K(14,3) : | 42.7 |
D(3) : | 27.5 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 94.9 | Low : | 13.22 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GPCR ] has closed below upper band by 25.9%. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 55.83 - 56.06 | 56.06 - 56.29 |
| Low: | 47.52 - 47.72 | 47.72 - 47.93 |
| Close: | 53.11 - 53.5 | 53.5 - 53.91 |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Thu, 02 Apr 2026
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8% - What's Next? - MarketBeat
Thu, 02 Apr 2026
Exchange Traded Concepts LLC Sells 32,241 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Wed, 01 Apr 2026
Weight Loss Drug-Maker Structure Therapeutics Stock Jumps On Eli Lilly News - Structure Therapeutics (NAS - Benzinga
Mon, 30 Mar 2026
Structure Therapeutics (GPCR) Is Down 5.5% After Strong Oral GLP-1 Phase 2 Data - What's Changed - sahmcapital.com
Sat, 28 Mar 2026
Structure Therapeutics (NASDAQ:GPCR) Stock Rating Lowered by Wall Street Zen - MarketBeat
Fri, 27 Mar 2026
Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster (GPCR) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 165 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 95.8 (%) |
| Shares Short | 5,260 (K) |
| Shares Short P.Month | 4,930 (K) |
| EPS | -2.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 21.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -9.4 % |
| Return on Equity (ttm) | -11.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -222 (M) |
| Levered Free Cash Flow | -180 (M) |
| PE Ratio | -22.29 |
| PEG Ratio | 0 |
| Price to Book value | 2.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|